Tyche Wealth Partners LLC Sells 2,015 Shares of Eli Lilly and Company $LLY

Key Points

• Tyche Wealth Partners cut its Eli Lilly stake by 39.4%, selling 2,015 shares in Q4 and now holds 3,101 shares valued at about $3,333,000.
• Eli Lilly recently posted a Q4 EPS beat with revenue of $19.29 billion (up 42.6% year‑over‑year) and set FY2026 guidance of $33.50–$35.00 EPS, while analysts maintain a consensus rating of "Moderate Buy" with a $1,224.59 target.
• Key operational catalysts and risks include positive ACHIEVE‑4 data and early Foundayo launch momentum (~1,390 first‑week U.S. prescriptions) offset by the FDA's request for additional post‑approval safety data and competitive pressure from Novo Nordisk.

Tyche Wealth Partners LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 39.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,101 shares of the company's stock after selling 2,015 shares during the quarter. Tyche Wealth Partners LLC's holdings in Eli Lilly and Company were worth $3,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after acquiring an additional 11,396 shares during the period. Rede Wealth LLC purchased a new position in Eli Lilly and Company during the 3rd quarter valued at $487,000. Cidel Asset Management Inc. boosted its holdings in Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after acquiring an additional 5,591 shares during the period. Spire Wealth Management boosted its holdings in Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after acquiring an additional 592 shares during the period. Finally, Coldstream Capital Management Inc. boosted its holdings in Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after acquiring an additional 8,659 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on LLY shares. Leerink Partners boosted their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an "outperform" rating in a report on Thursday, February 5th. Barclays started coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price objective for the company. HSBC cut Eli Lilly and Company from a "hold" rating to a "reduce" rating and dropped their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Finally, Guggenheim dropped their price objective on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating for the company in a report on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,224.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late‑stage ACHIEVE‑4 trial showed cardiovascular benefit (including a large reduction in all‑cause death in a pre‑planned analysis) and non‑inferiority vs. insulin — strengthens Foundayo’s safety/efficacy profile and supports use in diabetes. ACHIEVE‑4 PR
• Positive Sentiment: Commercial launch momentum: Foundayo recorded ~1,390 U.S. prescriptions in its first week, showing initial demand that supports broader revenue upside if uptake continues. Foundayo first‑week scripts
• Positive Sentiment: Analyst sentiment and revenue drivers remain constructive: Mounjaro, Zepbound and Foundayo sales are expected to support strong Q1 revenue — Lilly set to report on April 30. These commercial tailwinds underpin the company’s long‑term growth case. Q1 sales expectations
• Positive Sentiment: Pipeline and M&A expansion: Lilly is acquiring CrossBridge Bio (~$300M reported) to bolster oncology capabilities — diversifies growth beyond obesity/diabetes. CrossBridge Bio acquisition
• Neutral Sentiment: CEO commentary: Lilly’s CEO said weight‑loss drugs may eventually reach ~50% of potential users due to system and cost limits — a realistic market sizing comment that tempers but does not negate the long‑term opportunity. CEO market penetration remarks
• Neutral Sentiment: New entrants and IPOs (e.g., Kailera) show sustained investor interest in GLP‑1/weight‑loss space — increases funding and competition but also validates sector growth. Kailera IPO
• Neutral Sentiment: Lilly confirmed its Q1 2026 results and conference call date (April 30) — a near‑term event that could reprice expectations based on revenue/volume detail. Earnings date confirmation
• Negative Sentiment: Regulatory scrutiny: The FDA has requested additional post‑approval safety data and postmarketing studies for Foundayo (notably liver and cardiovascular signals), creating uncertainty around labeling, payer coverage and adoption. This prompted earlier selling pressure. FDA safety data request
• Negative Sentiment: Competitive/clinical nuance: A recent study suggested Novo Nordisk’s oral agent may better preserve lean body mass versus Lilly’s tirzepatide in some analyses — a potential marketing/clinical drawback to monitor. Lean mass study
• Negative Sentiment: Some outlets noted Foundayo’s initial scripts trail Novo’s oral product in early uptake — underscores competitive pressure in the U.S. obesity market. Launch comparison with Novo

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $926.90 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market capitalization of $875.75 billion, a price-to-earnings ratio of 40.39, a P/E/G ratio of 1.05 and a beta of 0.51. The stock has a fifty day simple moving average of $971.16 and a two-hundred day simple moving average of $980.76. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same period in the prior year, the business earned $5.32 EPS. The business's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.